Bristol-Myers Squibb (BMY) Reports Q4 Revenue Up 1.4% to $12.5B, Beats Estimates

Bristol-Myers Squibb (NYSE:BMY) reported Q4 CY2025 revenue of $12.5 billion, up 1.4% year-on-year and 1.8% quarter-over-quarter, beating analysts’ estimates. Non-GAAP profit of $1.26 per share was 4.6% above consensus, and the company’s full-year revenue guidance of $46.75 billion is 5.7% above estimates. Over the past two years, the company’s Growth Portfolio delivered 16.7% average YoY sales growth, outpacing total revenue. Operating margin expanded 7.9 percentage points to 11.8% in Q4, reflecting operating leverage. EPS for the quarter rose to $1.26 from $1.67 a year ago, while next-year full-year EPS is forecast at $6.15, down 3% from 2024. Looking ahead, sell-side analysts project revenue to decline 7.8% over the next 12 months. The stock rose $0.78 or 1.3% to $58.35 in after-hours trading on the results.